Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations

NCT03012191 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03012191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03012191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations
Lead sponsor
University of Southern California
Phase
Phase 1/2
Overall status
Completed
Start date
February 2, 2017
Completion date
August 31, 2018
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recessive dystrophic epidermolysis bullosa